Antibody to watch: neutralizing SARS-CoV-2 antibody from recovered COVID-19 patient

•  We take advantage of our universal HybriFree antibody discovery platform to efficiently discover therapeutic antibody candidates by direct cloning from COVID-19-recovered patients’ blood samples 
• HybriFree method is further powered by our patented QMCF protein expression platform, permitting high-quality recombinant antigen and antibody production for pre-clinical research (including afucosylated antibodies for enhanced ADCC) 
• Both technologies and relevant case studies will be presented, and discussed

Mart Ustav Jr., CSO, Icosagen